# Daniel Wagner

> Daniel (Dan) Wagner is a medical device and biotechnology executive who leads Otolith Labs, the Washington, DC company building the OtoBand, a non-invasive wearable that uses patented non-invasive Vestibular Resonance Therapy (nVRT) to address chronic vertigo. With more than two decades of commercial experience spanning 60-plus countries and roles at Spark Biomedical, Olympus Corporation, HeartSciences and Signature Biologics, Wagner advised Otolith for over five years before joining full-time as Chief Commercial Officer in 2024 and now serves as Chief Executive Officer, steering the company's go-to-market strategy toward a planned market launch.

- **Role:** Chief Executive Officer at Otolith Labs
- **Organizations:** Otolith Labs, Spark Biomedical, Signature Biologics, HeartSciences, Olympus Corporation
- **Nationality:** American
- **Known for:** More than two decades of executive experience in medical device and biotechnology, Commercial experience spanning 60-plus countries and 12-plus healthcare specialties, Led corporate growth initiatives across capital equipment, diagnostics, therapeutics, DME and biologics

## Career timeline

- **2000s-2010s** — Held leadership positions at Olympus Corporation across global capital equipment and medical device markets
- **2010s** — Executive roles at HeartSciences and Signature Biologics
- **~2019** — Began serving as an advisor to Otolith Labs, a relationship that lasted more than five years
- **2020s** — Chief Commercial Officer at Spark Biomedical
- **2024-02** — Appointed Chief Commercial Officer at Otolith Labs, joining full-time to lead go-to-market strategy
- **2024-2025** — Elevated to Chief Executive Officer at Otolith Labs per company biography

## Achievements

- More than two decades of executive experience in medical device and biotechnology
- Commercial experience spanning 60-plus countries and 12-plus healthcare specialties
- Led corporate growth initiatives across capital equipment, diagnostics, therapeutics, DME and biologics
- Building Otolith Labs' commercialization infrastructure across market access, medical affairs, sales operations and marketing
- Steering go-to-market strategy for the OtoBand, a wearable with FDA Breakthrough Device Designation

## Latest updates

- **2024-02** — Appointed Chief Commercial Officer at Otolith Labs alongside the addition of Raphael Michel to the board of directors.
- **2025-01** — Listed as Chief Executive Officer on Otolith Labs' company biography, leading go-to-market and operational buildout.

## Links

- Website: https://otolithlabs.com
- LinkedIn: http://www.linkedin.com/in/daniel-wagner-2a59137

---

Profile page: https://yespress.io/daniel-wagner
Published by YesPress — https://yespress.io
Last updated: 2026-07-22